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Cancer is a disease initiated and propelled forward by the accumulation and interaction of genetic and
epigenetic mutations of genes involved in the regulation of cell signaling and growth. Epigenetics refers
to the heritable alterations in gene expression, not attributable to changes in DNA sequence. The two
predominant epigenetic mechanisms are DNA methylation and histone modiﬁcation. The role of epi-
genetics in the regulation of gene expression has been considered as a basic pathway in the progression
and pathogenesis of various malignancies, such as cancers of the urogenital organs. Recently, several
studies have focused on the epigenetics of male urogenital system cancers. Epigenetic modiﬁcations in
the DNA of cancer patients and precancerous lesions provide the promise of novel biomarkers for early
cancer prediction, diagnosis, prognosis, and treatment response. In addition, numerous epigenetic
modiﬁcations represent a potential goal of novel therapeutic strategies and treatment design. Ultimately,
pioneering diagnostic methods and treatment regimens probably will be based on epigenetic mecha-
nisms and included into medical practices that address the needs of patients with male urogenital organ
cancers.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Previously, cancer had been viewed primarily as a genetic dis-
order.1 However, it has recently become generally accepted that
cancer is not only inﬂuenced by genetic factors2,3 but also by the
consequences of abnormal epigenetic events.4 Genetic alterations
and aneuploidy are linked to changes in the DNA sequence, and are
true hallmarks of malignant pathogenesis.5,6 Epigenetic changes
commonly exist in human cancers as a consequence of heritable
alterations in gene expression7e9 and chromatin structure,10,11
which are transmitted to several cell generations without alter-
ations in DNA sequence.12,13 This results in functional costs which
correspond to those induced by genetic changes.14,15 Signiﬁcantly,
intriguing evidence has emerged indicating that epigenetic modi-
ﬁcations may lead and actually provoke genetic alterations.16,17 In
this scenario, the epigenetic events are main events while geneticand Biochemistry, Faculty of
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Society. Production and hosting bychanges (for example mutations) are basically a consequence of the
epigenetic disruption.18,19 This information may clarify why
numerous genetic screens proved to be imperfect with regard to
cancer pathogenesis and causality. Aberrant epigenetic events in-
ﬂuence cellular pathways20 and multiple genes21,22 in a non-
random fashion, and thus can predispose the beginning and accu-
mulation of genetic alterations in the course of tumor initiation23
and development.24 These considerations are crucial for a better
understanding of tumor pathogenesis,25 cellular and molecular
processes26 underlying the acquisition of drug resistance,27,28 in
addition to the development of cancer therapy,29,30 control and
prevention strategies.31,32
1.1. DNA methylation and carcinogenesis
DNA methylation is deﬁned as the subtraction or addition of a
methyl group to a cytosine residue in DNA sequence.33 The
methylation of DNA is controlled by DNA methyltransferase en-
zymes.34 In genome-wide association studies, global decreases in
DNA methylation (hypomethylation) are functionally related when
they occur in transcriptional regions of genes,35 resulting in alter-
native translations or mRNA levels.36 It is believed thatElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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tating mitotic recombination,37 leading to translocations,38 de-
letions,39 and chromosomal rearrangements. The addition of
methyl groups (hypermethylation) is much more gene precise.40
The DNA sequences rich in residues of a cytosine preceding a
guanine (CpG dinucleotide) are called CpG islands.41 In particular,
CpG islands occur in the promoter of about half of all genes.42 The
hypermethylation of promoter (CpG islands) results in their tran-
scriptional silencing of protein expression43 (Fig. 1). Therefore,
hypermethylation of tumor suppressor genes is currently recog-
nized to be a means of providing a silencing alternative to mutation
or allelic loss in cancer development.44
Hypermethylation of genes is also involved in the DNA repair,45
cell cycle,46 carcinogens metabolism,47 apoptosis,48 and cellecell
interaction49 which have been implicated in carcinogenesis.
Furthermore, hypermethylation can also inhibit the transcription of
microRNA leading to carcinogenesis.50 However, it should be taken
into account that hypermethylation also occurs in normal physio-
logical process,51 for instance during inactivation of the second X
chromosome in females.52 The question is posed as towhy aberrant
DNAmethylation occurs, yet remains incompletely understood. It is
known that some genes are methylated in an age-related style,53,54
whereas others are methylated in a cancer-speciﬁc manner.55
Deﬁnitely, one carcinogenetic pathway of particular relevance to
the reproductive system is the CpG regions methylator phenotype
(CIMP). CIMPþ cancers have different genetic, pathologic and
clinical features.56e58 Whether environmental factors such as car-
cinogens, diet (e.g., folic acid), or other unknown causative agents
contribute to DNA methylation remains to be elucidated and
continue to be areas of research interest.1.2. Histone modiﬁcations and cancer
Histones are protein molecules of the chromatin, the structure
around which DNA is wound (Fig. 2). Histones may undergo a
number of types of post-translational modiﬁcations, such as
methylation, acetylation,59 phosphorylation,60 and ubiquitina-
tion.61 These modiﬁcations can inﬂuence interactions between
DNA and histones, resulting in the alteration of gene transcrip-
tion,62 DNA repair,63 DNA replication,64 in addition to organization
of chromosomes.65 Universally, histone acetylation is associated
with transcriptional activation.66 Consequently, deacetylation is
involved in tumor suppressor gene silencing during carcinogen-
esis.67 Indeed, inhibitors of histone deacetylase are in early phaseFig. 1. DNA methylation and its role in traclinical trials for medications targeting a number of cancers, with
promising results.68,69
Histone methylation occurs mostly at arginines (R) and lysines
(K). Methylation by histone post-translational modiﬁcations (PTM)
have a number of substantial differences compared to the above-
described acetylation. Lysines can be monomethylated, dimethy-
lated, or trimethylated, while arginines can be only mono-
methylated or dimethylated. In arginine methylation, asymmetric
or symmetric dimethylation should be distinguished because ac-
curate methyl designation are important for functional outcomes.
As opposed to acetylation, the addition of a single methyl group on
the side chain does not change its charge, and consequently it is
unlikely that methylation can directly alter nucleosomal in-
teractions which are essential for chromatin folding. Another
diverse characteristic of histone methylation is that it has been
involved in both transcriptional repression and activation. For
instance, trimethylation of H3K9, H4K20 (H4K20me3), and H3K27
was found to be implicated in transcriptional silencing, while tri-
methylation at H3K36 and H3K4 (H3K4me3) serve as active
marks.70 Methylation of arginine, catalyzed by arginine methyl-
transferases, can serve as a transcriptional repressor or activator.71
Lysine methylation has been described on all 4 cores of histone
types, in addition to histone H1. Additionally, H14K26 was found to
be the ﬁrst methylation site studied in H1.72
Methylation of histones is considered to be a critical step
involved in many cell fate determinations, including cell differen-
tiation and development processes73 pluripotency74 and mainte-
nance of genome integrity.75 Methylation of histones has also been
associated withmalignancy and other disorders76 (about 50% of the
histone methyltransferase encoded by the human genome are
highly associated with diseases and in particular tumorigenesis).
1.3. CpG island methylator phenotype criteria (CIMP)
In 1999, two different types of colorectal cancerswere identiﬁed,
and found to display low and high levels of tumor-speciﬁc methyl-
ation, correspondingly.77,78 The latter type of cancer was found to
exhibit a “CpG island methylator phenotype” (CIMP).79 CIMP is
negatively linked with genetic aberrations in colorectal cancer,80,81
which implies that it can offer an alternative pathway for carcino-
genesis.82 Other cancers that show frequent and concomitant
deactivation of several genes via hypermethylation also have been
designated as CIMP. These cancers include liver,83 gastric,84
leukaemia,85 lung,86,87 and ovarian cancers.88 Differential expres-
sion of the DNA methyltransferase (DNMT) genes in some ovariannscriptional inactivation and cancer.
Fig. 2. Histone modiﬁcations.
Table 1
Genes or miRNAs that epigenetically silenced or regulated in male urogenital organs
cancer.
Gene/MiRNA Organ References
Calc, ER, E-Cad, P15, P16, HICI, Rb and
GSTP1
Prostate [171]
PMP24 Prostate [172]
TMS1/ASC Prostate [173]
14-3-3sigma Prostate [174]
EFEMP1 Prostate [175]
POU5F1 and RASSF1A Testis [176]
DAP-kinase Bladder [177]
DBCCR1 Bladder [178]
GDF15, TMEFF2, VIM Bladder [179]
P16INK4A, RASSF1A, PRSS3, and SFRP Bladder [180]
EZH2 Bladder [181,182]
miR-21, miR-34a, miR-34b, miR-141,
miR-145, miR-193b,196b, miR-200c,
miR-205, miR-miR-615
Prostate [183]
miR-29 family, miR-34b, miR-101, miR-
34b, miR-499a, miR-17-5p
Prostate [183]
miR-132, miR-127 Prostate [50]
miR-1224, miR-205 Bladder [50]
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expression might contribute to develop CIMP phenotype in ovarian
cancer.90,91 Yet, the basicmechanisms that contribute to increases of
methylation abnormalities in ovarian cancer cells remain unclear.
Numerous studies have demonstrated that patients with CIMP -
positive tumors generally have a poor prognosis possibly due to
increases of their epigenetic plasticity.92e94 Therefore, it will be
important to determine the molecular basis of CIMP, but also to test
the present set of methylation biomarkers for detection of CIMP.94,95
However, CIMP-positive tumors are easier to diagnose at an early
stage because aberrant DNA methylation can be detected with a
high level of sensitivity.96 Also, this phenotype may be able to pre-
dict treatment outcomes in ovarian cancer patients.97,98 Generally,
the compactness of methylated CpG sites within a locus in addition
to the number of methylated loci were found to be increased in the
late stages of cancer.99 While the duration of progression-free sur-
vival after chemotherapy was found to be considerably shorter for
patients with high levels of methylation compared to those with
lowermethylation levels,66 enhanced detection of CIMP tumorsmay
aid in treatment planning and outcome.
1.4. MicroRNAs and cancer
MicroRNAs (miRNAs) are known as small non-coding regulatory
RNAs typically found in sizes ranging from 17 to 25 nucleotides. This
deﬁnition of miRNAs is based on their production via the action of
the enzyme Dicer, an RNase that processes hairpin structured pre-
cursors into mature miRNAs.100 MiRNAs post-transcriptionally
repress gene expression via recognition of complementary target
sites in the 30 untranslated region (UTR) of target mRNAs.
MicroRNAs play vital roles in a variety of functions in the cell
such as cell development, differentiation, cell cycle involvement
and apoptosis.101 The expression of miRNA is deregulated in ma-
lignancy by a variety of mechanisms including ampliﬁcation, mu-
tation, deletion, and epigenetic silencing. Several reports have
indicated the involvement of miRNAs in cancer initiation and
progression.102 Importantly, there are three different epigenetic
modiﬁcations i.e., DNA methylation, histone modiﬁcation and
miRNAs interaction and their inﬂuence with each other.103 For
example, miRNA expression can be regulated via DNA methylation
in the respective regions of their promoter.104 Likewise, miRNAs can
target chromatin remodeling enzymes105 and DNAmethyltransferases (DNMTs)106 and, therefore, modulate the
downstream effects. Genes or miRNAs that are epigenetically
silenced or regulated in male urogenital organs cancer are sum-
marized in Table 1.
1.5. Prostate cancer
Prostate cancer is one of the most widespread cancers affecting
men, with more than 1,100,000 new cases and 300,000 annual
deaths globally.107 The disease occurs more frequently among older
men, with amiddle age at diagnosis of somewhat above 60 years.107
Prostate cancer is predominantly a medical problem that requires
urgent attention as the disease is indolent, shows prolonged la-
tency and is associated with high morbidity and mortality.108
Epigenetic modiﬁcations have been found to play critical roles in
prostate cancer development and metastasis.109
1.6. Epigenetic modiﬁcations in prostate cancer
Prostate cancer is one of the most frequent humanmalignancies
and is driven by genetic and epigenetic modiﬁcations.110 Such
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ﬁcations, and microRNAs (miRNA) which produce heritable alter-
ations in gene expression without changing the DNA sequence.
Aberrant DNA methylation (hypomethylation and hyper-
methylation) is the most extensively characterized alteration in
prostate cancer and leads to instability of genome and improper
gene expression. Global and locus-speciﬁc alterations in chromatin
rearrangement are associated with prostate cancer, suggesting a
causative malfunction of histone-modifying enzymes. In addition,
microRNA deregulation contributes to the carcinogenesis of pros-
tate cancer, including interference with apoptosis and androgen
receptor signaling pathways. There are signiﬁcant relations be-
tween common genetic alterations and changes in the epigenetic
landscape.
1.7. The role of hypomethylation in prostate cancer
Hypomethylation is the most commonly observed methylation
problem seen in a wide variety of cancers including prostate can-
cer.111 Hypermethylation alterations seem to precede hypo-
methylation alterations, which are usually detected in late stage
cancers, and occur heterogeneously during prostate cancer devel-
opment and metastatic dissemination.109 Hypomethylation has
been proposed to contribute to oncogenesis via several mecha-
nisms including: activation of oncogenes for instance H-RAS and c-
MYC, activation of latent retrotransposons, and through contrib-
uting to chromosome unsteadiness.112 Recent reports have
conﬁrmed a strong association between MYC upregulation in
prostate cancer cell and clinical progression.113 MYC plays a crucial
role in androgen-dependent growth, and subsequent to its ectopic
expression can stimulate androgen-independent growth in pros-
tate cancer tissue.109
1.8. The role of hypermethylation in prostate cancer
The majority of studies focused on DNA hypermethylation have
been done in the epigenetic ﬁeld of prostate cancer.114 Certainly,
gene silencing is found to be more frequently facilitated by
hypermethylation of the promoter region compared to mutations
in carcinogenesis.115 Many studies focusing on different hyper-
methylated genes in different types of cancers propose the main
part of the carcinogenesis.116
At present, more than 100 genes have been detected for their
frequencies of hypermethylation and their critical role in prostate
carcinogenesis.117e121 Several of those hypermethylated genes are
tumor suppressor genes that code for the proteins that control the
cell cycle and/or endorse apoptosis. The roles of tumor suppressor
genes in prostate cancer can be separated into ﬁve main categories:
cell cycle, DNA repair, apoptosis, invasion/metastasis, and cortico-
steroid hormonal response. Loss of function of these genes via
promoter hypermethylation ultimately contributes to the carcino-
genesis and pathogenesis of prostate cancer.
1.9. The role of histone modiﬁcation in prostate cancer
Histone modiﬁcations play a critical role in both normal and
cancer cells, becoming an orchestrating key of physiological and
pathological processes.122 In prostate cell lines, methylation of
lysine 9 in histone 3 (H3K9) is associated with histone H3K4
methylation, and repression of androgen receptor (AR) genes109 is
linked to AR gene activation in castration-resistant prostate cancer
(CRPC) cell lines and tissues.109 H3K4 is signiﬁcantly methylated at
the androgen receptor enhancer of the proto-oncogene (ubiquitin-
conjugating enzyme E2C) UBE2C gene in CRPC, which cause
androgen receptor binding and expression of UBE2CmRNA.109 Heatshock protein 90 has also been found to play a critical role in
androgen-induced and -independent nuclear localization and
activation of AR. Histone deacetylase 6 (HDAC6) regulates AR hy-
persensitivity and nuclear localization, mainly through modulating
Tumor Necrosis Factor Receptor-Associated Protein-1 (TRAP1)
acetylation.123
1.10. The role of MicroRNAs in prostate cancer
The miRNAs are small, noncoding molecules of RNAs consisting
of 18e22 nucleotides, and bind to the 30 untranslated region of
mRNAs.124 They play critical roles in post-transcriptional degrada-
tion or inhibition of target mRNA, depending on the level of com-
plementary base pairing.125e127 Thus, miRNAs play a vital role in
the regulation of many cell and tissue functions, including cell
differentiation, development, metabolism and cell cycle.128e130
Aberrant expression of miRNAs is found to have critical impact on
a variety of biological processes such as infection and cancer
development.128,131,132
The role of miRNAs in cellular differentiation, growth, and
apoptosis of cancer cells via their targeting mRNA has been previ-
ously reported.133e135 MiRNAs may be tumor suppressors or
oncogenic molecules,135,136 with tumor suppressors being down-
regulated and oncogenic molecules being upregulated in cancers.
Commonly, the roles of miRNAs in the cancer has been emphasized
by the fact that approximately 50% of all miRNA genes are located in
the so called 'fragile sites', the cancer associated genomic regions
that are frequently altered in cancer. A bulk of data has already been
documented about aberrant expression of miRNAs in the cancers.
However, an understanding of the functional consequences of these
abnormalities has not been molecularly developed.137
The role of miRNAs in prostate cancer is getting clearer by un-
derstanding the interactions between miRNAs and their targeted
mRNAs and the consequential impact on carcinogenesis of the
prostate cancer.138,139 It has been found that miRNAs and their
targeted mRNA are aberrantly expressed in prostate cancers which,
in turn, change the cellular invasion, growth, and metastatic po-
tential of prostate cancer cells. The deregulation of certain miRNAs
expressions are now considered crucial biomarkers for the classi-
ﬁcation, prognosis and diagnosis of prostate cancer.135,140,141 All of
the above-mentioned data highlight the signiﬁcance of the biology
of miRNAs in prostate cancer. Their speciﬁc deregulations, and how
to control their expressions will possibly become novel avenues
through which newer therapeutic strategies might be developed
for the medication of metastatic castration-resistant prostate can-
cer. Several types of miRNA play a crucial role in prostate cancer, for
example, miRNA-488,142 miRNA -221 and miRNA-222.143 Addi-
tionally, the role of miRNAs in prostate cancer progression is
summarized in Table 2.
1.11. Bladder cancer
Bladder cancer is one of the most widely dispersed cancers and
is the seventh most common cancer in the world.144 Cigarette-
smoking, exposure to chemicals (for example aromatic amines),
bladder inﬂammation, genetic factors, and age are risk factors
associated with the development of bladder tumor.145,146 In the
United States, over 90% of bladder cancers are diagnosed as uro-
thelial carcinoma, 2% as adenocarcinomas and 5% as squamous-cell
carcinoma.147 In tropical countries, where chronic urinary infection
caused by Schistosoma haematobium is widespread, the majority of
bladder cancers are squamous-cell carcinoma.148
At present, a number of histone modiﬁcations and the aberrant
expression of miRNAs have been associated with tumorigenesis
and have also been identiﬁed as strong biomarkers for cancer of the
Table 2
The role of miRNAs in prostate cancer progression.
Type of miRNA Role in prostate
cancer
Functions
miR-15a
and miR-16
Tumor suppressors Inhibit cell proliferation, invasion and
angiogenesis
via regulation of multiple mRNA targets
miR-21 Onco-miRNA Increases tumor growth, invasion and
metastasis
miR-125b Onco-miRNA Inhibits apoptosis and increases cell
proliferation
miR-143 Tumor suppressor Inhibits cell proliferation and migration
by regulating KRAS,
MAPK pathways and cell cycle. Also
inhibits metastasis
miR-145 Tumor suppressor Inhibits migration, invasion and
metastasis
miR-200 s Tumor suppressor Inhibit cell migration and invasion by
reversing EMT
miR-221 Onco-miRNA Stimulates cell growth and inﬂuences
cell cycle progression
miR-222 Onco miRNA Increased cell cycle progression
miR-488 Onco-miRNA Increased cell cycle progression
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stable in body ﬂuids because of their small sizes and therefore are
resistant to degradation by nucleases, as well as frequently diag-
nosed through lab analysis.149
1.12. Epigenetic biomarkers of bladder cancer
Genetic and epigenetic changes are hallmarks of human tumor.
Over the last few decades, it has become well-established that
epigenetic modiﬁcations are important events in cancer progres-
sion and development besides just genetic alterations, for instance
chromosomal reorganizations, aneuploidies and point mutations.
Numerous genes have been detected that become hypermethylated
in the tissue or urine samples of bladder cancer patients. Hyper-
methylation of these genes was found to be associated with their
downregulation, which has some clinical signiﬁcance to the
development and progression of bladder cancer (Table 3).
1.13. Testicular cancer
Testicular tumor (TC) is an unusual cancer which comprises 1%
of cancers in men. Nevertheless, it is the most frequently diagnosed
tumor in men in their 20s and 30s.150 Additionally, TC poses aTable 3
Hypermethylation of genes with clinical signiﬁcance in the developm
Full name of gene
ABCC6, ALX4,, APBA1, BRCA1, CFTR, CDH13, HPSE, MT1A, RASSF1A
APC, GSTP1 and RARRES1
GDF15, TMEFF2, VIM,
APC, CDH1, RASSF1A
DKK3, SFRP1, SFRP2, SFRP4, SFRP5, WIF1
APC, ARF, CDKN2A, CDH1, GSTP1, MGMT, RARB, RASSF1A and TIM
BCL2, DAPK1 and TERT
APC, CDKN2A and RASSF1A
CDKN2A, CDH1, DAPK1 and RARB
NID2 and TWIST1
RARB
RUNX3
RASSF1A
A2BP1, CA10, DBC1, MYO3A, NPTX2, NKX6-2, and PENK, SOX11
APC, CDH1, CDH13, DAPK, FHIT, GSTP1, MGMT, SSF1A, RARb and p
APC, BCL2, CDKN2A, CDH13, CDH1, OPCML, RASSF1A and TIMP3
DAPK1, H19 and TIMP3genuine sterility problem which affects men throughout their
reproductive period. Interestingly, the development of testicular
cancer is associated with urogenital disorders.151 Testicular cancer
development also has been linked to hypospadia, cryptorchidism
and low fertility. In fact, epidemiological studies dispute whether
there is an increased risk of testicular germ cell tumor inmales who
experience fertility troubles.152
1.14. Epigenetic modiﬁcation in testicular cancer
DNA methylation plays a critical role during germ cell devel-
opment. These epigenetic modiﬁcations rely on DNA methyl-
transferases (DNMTs); among these enzymes, the expression
proﬁles of DNMT3a and DNMT3l propose that they may function
during embryonic germ cell development for the organization of de
novo DNA methylation. On the other hand, DNMT1 and DNMT3b
are found to apparently increase following the birth in male.153
Thus, it is assumed that these two enzymes may be implicated in
the maintenance of DNA methylation patterns in the proliferation
of spermatogonia.
1.15. DNA methylation
The major role of epigenetic modiﬁcations has been reported to
be in carcinogenesis. Certainly, it has been found that DNA
methylation is linked with repression of the expression of the tu-
mor suppressor gene. This epigenetic alteration is one of the most
frequently studied in the cancer research ﬁeld, and has been
documented as a major mechanism during testicular cancer pro-
gression.154,155 The DNAmethylation patterns seem to be associated
with histological characteristics of the different types of testicular
cancer. Dnmt1 was not expressed in seminoma; however, it was
over expressed in embryonic carcinoma.156 In contrast, the
expression of Dnmt3a was found to be over expressed in testicular
cancer compared to non-tumor testicular tissues.157 The pattern of
Dnmt3b expression has been extensively studied, and demon-
strated that it could be used as a prognostic biomarker for relapse of
stage I seminomas.158 Additionally, it was further observed that
Dnmt3l was upregulated in the non-seminoma tumors.159
1.16. Histone modiﬁcations
The most important role of histone acetylation during the
spermatogenesis is the histone H4 hyperacetylation during sper-
miogenesis.160 This process seems to play a critical role forent and progression of bladder cancer.
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which is a fundamental characteristic for nucleus condensation and
consequently formation of spermatozoa. There are several mem-
bers divided in different subfamilies. Interestingly, choriocarci-
nomas displayed a commonly high expression for all three classes I
of HDAC isoforms.161 In contrast with other types of cancers, no
diagnostic or predictive values for HDAC1e3 in testicular cancer
could be inferred.162
1.17. Imprinting genes in testicular cancer
Genomic imprinting is one of the epigenetic mechanisms that
induces functional differences between maternal and paternal ge-
nomes, and plays a crucial role in mammalian embryonic devel-
opment. The differential methylation of CpG islands in critical
regions of imprinted genes is the mechanism of the imprinting
progression that differentiates maternal and paternal alleles.163
Maternally expressed H19 is one of the most well-characterized
imprinted genes. Expressions of imprinted genes, for instance
H19, in the germ line become biallelic at day 11.5 during embryonic
development.164,165
The 50-region of H19 is usually methylated on the paternal allele
in human genomes.166 It has been shown that fetal spermatogonia
are mainly unmethylated at the differentially methylated CpG re-
gions of H19, while adult testicular germ cells show signiﬁcant
methylation at the same CpG regions.167 These phenomena are
considered to be “DNA reprogramming”, which are seen in
genome-wide survey of germ cells or pre-implantation embryos.168
It has also been determined that complete epigenetic reprogram-
ming occurs within 1 day of the embryonic developmental period
in mouse primordial germ cells after reaching the genital
crest.167,169 In addition, loss of allele-speciﬁc imprinted gene
methylation has also been seen in both male and female primordial
mouse germ cells.170 These data support the notion that pre-
existing imprints are erased in the germ line by this stage.
2. Conclusion and future directions
Cancer epigenetics offer scientists hope to understand the
complexity of interactions from the genetic code to eventual
cellular fate.
Since the number of known genes that undergo aberrant
epigenetic deactivation linked with male urogenital organs cancers
is growing, a number of questions need to be answered before we
completely understand the biologic implication and outcome of
this process. For instance, what is the mechanism deriving selective
methylation of genes in male urogenital organs cancers which in-
creases the activity and expression of DNMTs. Why do hyper-
methylation and hypomethylation occur in male urogenital organs
cancer cells? Is there an active demethylating process that can
explain hypomethylation, or it is caused by reduced
hypermethylation?
Scientiﬁc evidence suggests that the detection of DNA methyl-
ation can serve as a promising cancer biomarker. In males some
genes shows adequate sensitivity and speciﬁcity in the detection of
cancers to guarantee further testing as a cancer biomarker in pa-
tients' body ﬂuids for example urine, serum, and semen. Further
work is required to focus on the identiﬁcation of novel aberrantly
methylated genes via high-throughput screening techniques such
as CpG island microarray assays as the gateway toward cancer
biomarker conﬁrmation. Moreover, the methylation ﬁngerprint
comprises several genes and may be more precise than that of in-
dividual genes in the early diagnosis and risk measurement of male
urogenital organs cancers and molecular detection of resected
specimens.Before the causes and consequences of global hypomethylation
in male urogenital organs cancers have been fully identiﬁed, the
therapeutics targeting DNMTs in cancer should be used with care
and discretion. Ideally, therapeutic treatment would involve se-
lective triggering of a set of methylated genes without unwanted
demethylating to the rest of the genome. Given the close rela-
tionship between DNA methylation and histone deacetylation in
epigenetic deactivation, a combination of both DNMT inhibitors
and histone deacetylation inhibitors may be an effective strategy
for the treatment of female cancer patients.
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